Navigation Links
PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
Date:4/22/2010

INCLINE VILLAGE, Nev., April 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will hold a conference call and webcast on Thursday, April 29 at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2010. The call and webcast will follow the release of the first quarter financial results after market close.

Conference Call Details

To access the live conference call via phone, please dial (800) 688-0836 from the United States and Canada or (617) 614-4072 internationally. The conference ID is 10899707. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through April 30, 2010, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 55966470.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
2. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
3. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
4. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
5. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
6. Sinobiopharma Announces Second Quarter 2010 Financial Results
7. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
8. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
9. Array BioPharma and Amgen Partner in Type 2 Diabetes
10. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
11. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):